Companies Dominating the Cell Reprogramming Landscape
- Bio-Techne
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Human Longevity Inc.
- Lineage Cell Therapeutics
- Mesoblast
- Advanced Cell Technology Inc
- Lonza
- STEMCELL Technologies Inc.
- Astellas Pharma Inc.
- ALSTEM
- Mogrify Limited
Browse Key Market Insights with Data Illustration:
In the News
- Mogrify Limited - Mogrify Limited and Astellas Pharma Inc. announced a collaboration to conduct research on in vivo regenerative medicines approaches to address sensorineural hearing loss. The collaboration will seek to recognize novel combinations of factors that are included in cell differentiation to generate new cochlear hair cells.
- Mesoblast - Mesoblast announced a partnership with Blood and Marrow Transplant Clinical Trials Network (BMT CTN) for a clinical investigation and carry out the study that will assess Ryoncil in individuals 12 years of age and older who have not responded to first-line therapies such as corticosteroids or ruxolitinib.
